Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 04 March, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Pfizer Ltd

About the Company - Pfizer Ltd

Pfizer Ltd. is a Public Limited Listed company incorporated on 21/11/1950 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24231MH1950PLC008311 and registration number is 008311. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 2610.99 Cr. and Equity Capital is Rs. 45.75 Cr. for the Year ended 31/03/2022.
PharmaceuticalsThe Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra
NamePosition Held
Ms. Meenakshi NevatiaManaging Director
Mr. Milind PatilExecutive Director (Finance) & CFO
Mr. Samir KaziExecutive Director
Mr. Sunil LalbhaiIndependent Director
Mr. Pradip ShahChairman & Ind.Director
Mr. Uday KhannaIndependent Director
Ms. Meena GaneshIndependent Director

Pfizer Ltd. Share Price Update

Share PriceValue
Previous Day₹4,506.05

Basic Stock Data of Pfizer Ltd

Market Cap 21,086 Cr.
Current Price 4,609
High / Low4,840/3,407
Stock P/E41.6
Book Value 715
Dividend Yield0.76 %
ROCE26.2 %
ROE19.8 %
Face Value 10.0

Data Source:

Competitors of Pfizer Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
J B Chemicals & Pharmaceuticals Ltd 23,892 Cr. 1,5401,940/87546.5 1750.58 %22.4 %17.6 % 1.00
Solara Active Pharma Sciences Ltd 1,663 Cr. 462507/286 4070.00 %1.80 %1.44 % 10.0
Sanofi India Ltd 20,081 Cr. 8,7199,380/5,33034.0 4412.22 %71.1 %51.5 % 10.0
Bafna Pharmaceuticals Ltd 213 Cr. 90.0126/77.018.9 34.80.00 %15.9 %16.4 % 10.0
Alembic Ltd 2,602 Cr. 101108/55.210.2 82.52.17 %4.18 %8.67 % 2.00
Industry Average9,690.20 Cr2,182.4021.92228.060.99%23.08%19.12%6.60

Pfizer Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit203197126286189195165192232203182111183
OPM %34%33%24%38%30%29%30%32%36%33%32%21%32%
Other Income12153712151817-11821327123336
Profit before tax18318013226917518414543415201165126201
Tax %28%22%24%26%18%22%13%25%25%25%21%26%26%
Net Profit1311411012001431441263331115113094149
EPS in Rs28.7230.8721.9843.7031.2531.4627.507.1268.0032.9328.3420.4432.56

Pfizer Ltd Quarterly Chart

Pfizer Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit197184239414433350501566574712836809679
OPM %18%18%22%22%22%18%25%27%27%32%32%33%29%
Other Income9251910944972321141671838163134109
Profit before tax278694340207470517548660642669773824692
Tax %33%27%35%66%35%35%34%35%21%26%21%24%
Net Profit18550322170305337360429509498613624523
EPS in Rs61.86168.6274.0115.2666.6773.6278.7193.79111.29108.77133.90136.38114.27
Dividend Payout %20%19%486%82%22%27%25%24%297%32%26%29%

Pfizer Ltd Profit & Loss Yearly Chart

Pfizer Ltd Growth

Compounded Sales Growth
10 Years:9%
5 Years:4%
3 Years:4%
Compounded Profit Growth
10 Years:11%
5 Years:11%
3 Years:6%
Stock Price CAGR
10 Years:15%
5 Years:7%
3 Years:0%
1 Year:21%
Return on Equity
10 Years:16%
5 Years:18%
3 Years:20%
Last Year:20%

Pfizer Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital30303046464646464646464646
Other Liabilities2773653186387228401,0049261,007810997752691
Total Liabilities1,5822,0609772,6142,8883,2613,6903,9404,4053,2663,9014,0014,006
Fixed Assets312620944925902950886973894869749731
Other Assets1,5021,9889091,6141,9232,3432,7393,0543,4322,3693,0303,2443,266
Total Assets1,5822,0609772,6142,8883,2613,6903,9404,4053,2663,9014,0014,006

Pfizer Ltd Reserves and Borrowings Chart

Pfizer Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 24-1613211334532933298323427667356
Cash from Investing Activity 27862610368-701-250-238351,530-469-575-36
Cash from Financing Activity -14-43-1,360-1-62-83-110-110-164-1,571-181-346
Net Cash Flow288567-1,125181-417-3-17231,690-1,613-88-26

Pfizer Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days474957322620293029182023
Inventory Days186181148191167148147189198199173175
Days Payable13816515616515717824521319713010291
Cash Conversion Cycle9565495836-10-696318791107
Working Capital Days717257-9-46-57-15-713-87
ROCE %23%19%29%24%22%17%21%23%20%23%29%26%

Pfizer Ltd Financial Efficiency Indicators Chart

Pfizer Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders1,45,9801,21,1531,21,1531,26,8081,25,2871,23,4491,22,0281,17,9501,17,1941,15,9881,16,9481,12,456

Pfizer Ltd Shareholding Pattern Chart

No. of Pfizer Ltd Shareholders

Pfizer Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Nippon India Small Cap Fund9479100.94387.2
Nippon India Multi Cap Fund3628480.65148.22
Aditya Birla Sun Life ELSS Tax Saver Fund3348740.96136.79
Nippon India Pharma Fund2932491.93119.79
Aditya Birla Sun Life MNC Fund - Div2243822.6391.66
Aditya Birla Sun Life MNC Fund - Gr2243822.6391.66
SBI Magnum Midcap Fund2060340.5884.16
HSBC Midcap Fund1553000.7263.44
DSP Equity Opportunities Fund1406460.657.45
DSP ELSS Tax Saver Fund1121090.3645.79

Pfizer Ltd ROCE Trend

Pfizer Ltd EPS Trend

Pfizer Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)128.50133.89108.77111.2893.78
Diluted EPS (Rs.)136.38133.89108.77111.2893.78
Cash EPS (Rs.)159.44159.03132.68133.85109.39
Book Value[Excl.RevalReserv]/Share (Rs.)701.05626.10523.07742.18658.22
Book Value[Incl.RevalReserv]/Share (Rs.)701.05626.10523.07742.18658.22
Dividend / Share (Rs.)70.0035.0035.00330.0022.50
Revenue From Operations / Share (Rs.)530.00570.71489.30470.31454.97
PBDIT / Share (Rs.)198.89196.37173.38165.37160.13
PBIT / Share (Rs.)175.82171.23149.47142.81144.52
PBT / Share (Rs.)180.11168.94146.17140.43144.24
Net Profit / Share (Rs.)136.38133.89108.77111.2993.78
PBDIT Margin (%)37.5234.4035.4335.1635.19
PBIT Margin (%)33.1730.0030.5430.3631.76
PBT Margin (%)33.9829.6029.8729.8631.70
Net Profit Margin (%)25.7323.4622.2223.6620.61
Return on Networth / Equity (%)19.4521.3820.7914.9914.24
Return on Capital Employeed (%)24.0525.7027.4418.4921.69
Return On Assets (%)15.5915.7015.2311.5510.88
Asset Turnover Ratio (%)0.610.720.580.510.54
Current Ratio (X)3.842.812.493.493.05
Quick Ratio (X)
Inventory Turnover Ratio (X)0.790.800.770.841.01
Dividend Payout Ratio (NP) (%)47.6526.13303.3824.3725.70
Dividend Payout Ratio (CP) (%)40.7622.00248.7020.2622.04
Earning Retention Ratio (%)52.3573.87-203.3875.6374.30
Cash Earning Retention Ratio (%)59.2478.00-148.7079.7477.96
Interest Coverage Ratio (X)67.9585.6452.5069.73567.90
Interest Coverage Ratio (Post Tax) (X)45.1359.3933.9347.92333.60
Enterprise Value (Cr.)13990.3218276.3719572.8116195.4013279.91
EV / Net Operating Revenue (X)5.777.008.747.536.38
EV / EBITDA (X)15.3820.3424.6721.4118.13
MarketCap / Net Operating Revenue (X)6.547.629.248.567.30
Retention Ratios (%)52.3473.86-203.3875.6274.29
Price / BV (X)4.946.958.645.425.04
Price / Net Operating Revenue (X)6.547.629.248.567.30

Pfizer Ltd Profitability Ratios (%)

Pfizer Ltd Liquidity Ratios

Pfizer Ltd Liquidity Ratios (%)

Pfizer Ltd Interest Coverage Ratios (%)

Pfizer Ltd Valuation Ratios

Fair Value / Intrinsic Value of Pfizer Ltd

Fair Value: ₹5934.07

The stock is undervalued by 28.75% compared to the current price ₹4609

*Investments are subject to market risks

Strength and Weakness of Pfizer Ltd

  1. The stock has a high average ROCE of 23.00%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -1.00, which is a positive sign.
  3. The company has higher reserves (2,345.77 cr) compared to borrowings (15.23 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (1.54 cr) and profit (562.62 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 178.83 and average Dividend Yield of 31.17%.
  2. The stock has a high average Cash Conversion Cycle of 45.50, which may not be favorable.

Should I Buy Pfizer Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Pfizer Ltd:
    1. Net Profit Margin: 25.73%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 24.05% (Industry Average ROCE: 16.03%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): 45.13
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 3.21
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✗ Stock P/E: 41.6 (Industry average Stock P/E: 32.74)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✗ Total Debt / Equity: N/A
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Pfizer Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE